Costello Asset Management INC Has $7.17 Million Position in Johnson & Johnson (NYSE:JNJ)

Costello Asset Management INC lessened its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 2.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,029 shares of the company’s stock after selling 979 shares during the period. Johnson & Johnson accounts for about 6.6% of Costello Asset Management INC’s investment portfolio, making the stock its 2nd biggest holding. Costello Asset Management INC’s holdings in Johnson & Johnson were worth $7,169,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC lifted its holdings in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Norges Bank bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $4,609,399,000. Capital International Investors lifted its stake in shares of Johnson & Johnson by 62.7% in the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock worth $4,605,627,000 after buying an additional 10,724,110 shares during the last quarter. Journey Strategic Wealth LLC boosted its holdings in shares of Johnson & Johnson by 161,420.2% during the 2nd quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock worth $1,204,404,000 after buying an additional 7,271,978 shares during the period. Finally, Morgan Stanley grew its stake in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $157.87 on Tuesday. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The firm has a market cap of $380.04 billion, a P/E ratio of 11.43, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The firm’s 50-day simple moving average is $158.18 and its 200-day simple moving average is $158.62.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company’s revenue was down 9.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.35 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Analysts Set New Price Targets

A number of research analysts have weighed in on JNJ shares. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $167.00 to $180.00 in a research report on Friday, December 1st. Raymond James increased their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Morgan Stanley reduced their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $176.14.

Read Our Latest Stock Report on JNJ

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is owned by insiders.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.